Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
DRRX 
Durect Corporation (DRRX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/13/2025: DRRX (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -25.96% | Avg. Invested days 23 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/13/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 19.09M USD | Price to earnings Ratio - | 1Y Target Price 5 |
Price to earnings Ratio - | 1Y Target Price 5 | ||
Volume (30-day avg) 167438 | Beta 0.59 | 52 Weeks Range 0.48 - 1.84 | Updated Date 06/15/2025 |
52 Weeks Range 0.48 - 1.84 | Updated Date 06/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.48 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -264.71% | Operating Margin (TTM) -1289.41% |
Management Effectiveness
Return on Assets (TTM) -41.39% | Return on Equity (TTM) -217.95% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 12814187 | Price to Sales(TTM) 10.29 |
Enterprise Value 12814187 | Price to Sales(TTM) 10.29 | ||
Enterprise Value to Revenue 6.9 | Enterprise Value to EBITDA -2.48 | Shares Outstanding 31042600 | Shares Floating 28229502 |
Shares Outstanding 31042600 | Shares Floating 28229502 | ||
Percent Insiders 11.21 | Percent Institutions 22.3 |
Analyst Ratings
Rating 4.33 | Target Price 6.75 | Buy - | Strong Buy 2 |
Buy - | Strong Buy 2 | ||
Hold 1 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Durect Corporation
Company Overview
History and Background
Durect Corporation was founded in 1998. It is a biopharmaceutical company focused on developing novel and durable therapeutics for chronic diseases and acute conditions. Significant milestones include FDA approvals of its products and strategic collaborations with other pharmaceutical companies.
Core Business Areas
- LACTEL Absorbable Polymers: Durect's LACTEL biodegradable polymers are used in a variety of drug delivery and medical device applications.
- ORADUR: ORADUR is Durect's sustained-release oral delivery technology.
- SABER: SABER is Durect's controlled-release injectable technology.
Leadership and Structure
James E. Brown is the President and CEO. The organizational structure includes departments focused on research and development, clinical trials, manufacturing, and commercialization.
Top Products and Market Share
Key Offerings
- POSIMIR: POSIMIR (bupivacaine solution) is a non-opioid, local anesthetic extended-release solution indicated for administration into the subacromial space to produce analgesia for up to 72 hours following arthroscopic subacromial decompression. Durect licensed the rights to POSIMIR to Sandoz. Market share information and revenue specific to POSIMIR is not publicly broken out. Competitors: Exparel (Pacira BioSciences).
- ALZET Osmotic Pumps: ALZET Osmotic Pumps are research tools used for controlled drug delivery in animal research. While exact market share is difficult to determine, ALZET pumps are widely used in preclinical research. Competitors: Other micro-infusion pumps and drug delivery systems.
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by high R&D costs, stringent regulatory requirements, and a competitive landscape. The drug delivery market is growing, driven by the need for improved drug efficacy and patient compliance.
Positioning
Durect is positioned as a specialty pharmaceutical company focused on developing innovative drug delivery technologies and products. Its competitive advantage lies in its proprietary drug delivery platforms.
Total Addressable Market (TAM)
The total addressable market for drug delivery technologies is estimated to be in the billions of dollars. Durect is positioned to capture a portion of this market through its proprietary technologies and partnerships.
Upturn SWOT Analysis
Strengths
- Proprietary drug delivery technologies (LACTEL, ORADUR, SABER)
- Partnerships with established pharmaceutical companies
- Experienced management team
- Existing revenue stream from ALZET pumps
Weaknesses
- Limited financial resources compared to larger pharmaceutical companies
- Dependence on partners for commercialization of some products
- History of net losses
- Small Market Capitalization
Opportunities
- Expansion of drug delivery technologies into new therapeutic areas
- Strategic acquisitions or licensing agreements
- Increasing demand for controlled-release drug delivery systems
- Further collaborations with pharmaceutical companies
Threats
- Competition from established pharmaceutical companies with greater resources
- Regulatory hurdles and clinical trial failures
- Generic competition
- Economic downturn impacting healthcare spending
Competitors and Market Share
Key Competitors
- Pacira BioSciences (PCRX)
- Alkermes (ALKS)
- Assertio Holdings, Inc. (ASRT)
Competitive Landscape
Durect competes with larger pharmaceutical companies and smaller specialty companies. Durect's competitive advantage lies in its proprietary drug delivery technologies, but it faces challenges in terms of financial resources and commercialization capabilities.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been dependent on product approvals, licensing agreements, and sales of ALZET pumps. Growth rates have fluctuated over time.
Future Projections: Future growth projections are based on analyst estimates and depend on the success of pipeline products and strategic partnerships. These growth projects would be reflected as increased sales and profit.
Recent Initiatives: Recent initiatives include advancing clinical trials of pipeline products and seeking new partnerships.
Summary
Durect Corporation is a biopharmaceutical company with proprietary drug delivery technologies. They face competition from larger companies. Durect's strengths are in its technology and partnerships, while weaknesses include limited resources. Advancing clinical trials and securing new partnerships are critical for their growth.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Durect Corporation Investor Relations
- SEC Filings
- Industry Reports
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Market share data and financial information should be verified with official sources.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Durect Corporation
Exchange NASDAQ | Headquaters Cupertino, CA, United States | ||
IPO Launch date 2000-09-28 | Co-Founder, CEO, President & Director Dr. James E. Brown D.V.M. | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 20 | Website https://www.durect.com |
Full time employees 20 | Website https://www.durect.com | ||
DURECT Corporation, a biopharmaceutical company, develops medicines based on its epigenetic regulator program. The company's lead product candidate includes larsucosterol, an endogenous, orally bioavailable small molecule to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as for the treatment of patients with metabolic dysfunction-associated steatohepatitis. The company also offers POSIMIR, a post-surgical pain product to deliver bupivacaine over three days in adults; PERSERIS, an injectable suspension for the treatment of schizophrenia in adults; and Methydur to treat attention deficit hyperactivity disorder. It has strategic collaboration and other agreements with Virginia Commonwealth University Intellectual Property Foundation and Innocoll Pharmaceuticals Limited. DURECT Corporation was incorporated in 1998 and is headquartered in Cupertino, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.